Citius Pharmaceuticals, Inc. · NASDAQ:CTXR

Citius Pharmaceuticals — Investor Presentation (January 2022)

28 slides from Citius Pharmaceuticals's investor presentation, January 2022

  1. Slide 1: Citius Pharmaceuticals Corporate Overview January 2022

    CLICK TO EDIT MASTER TITLE STYLE Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) Corporate Overview JANUARY 2022 NASDAQ: CTXR

  2. Slide 2: Forward-Looking Statements

    CLICK TO EDIT MASTER STATEMENTS FORWARD-LOOKING TITLE STYLE This presentation has been prepared by Citius Pharmaceuticals, Inc. (the “Company”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promi

  3. Slide 3: Citius: Building a Biotech Platform

    CLICK CITIUS:TO EDIT MASTER BUILDING TITLEPLATFORM A BIOTECH STYLE Citius is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products LMB merges with Citius CTXR raises Multiple catalysts Pharmaceuticals, Inc. (CTXR); $127.6M

  4. Slide 4: Investment Highlights

    CLICK TO EDITHIGHLIGHTS INVESTMENT MASTER TITLE STYLE • Five Active Programs • I/ONTAK: purified reformulation of IL-2 diphtheria toxin fusion protein for CTCL DIVERSIFIED PHASE 3 • Mino-Lok® : potential to be first and only FDA-approved product to salvage infected PIPELINE WITH CVCs causing CRBSI/C

  5. Slide 5: Diversified Pipeline with Five Active Programs

    CLICK TO EDIT DIVERSIFIED MASTERWITH PIPELINE TITLEFIVE STYLE ACTIVE PROGRAMS ESTIMATED INVESTIGATIONAL ANTICIPATED PROGRAM MARKET PRECLINICAL PHASE I PHASE II PHASE III INDICATION MILESTONES (WW) I/ONTAK IL-2R CANCER >$300M BLA 2022 (E7777) IMMUNOTHERAPY* MINO-LOK® TREAT CVC > $1.8B End Ph 3 2022 (

  6. Slide 6: I/ONTAK

    CLICK TO EDIT MASTER TITLE STYLE I/ONTAK PHASE 3 NASDAQ: CTXR 6

  7. Slide 7: I/ONTAK: Cancer Agent Nearing FDA Submission

    CLICK TOPHASE I/ONTAK: EDIT MASTER TITLE 3 CANCER STYLE AGENT NEARING FDA SUBMISSION Novel oncology asset with an attractive near-term revenue opportunity and substantially de-risked path to support commercial success Near-term opportunity in Enrollment in BLA cutaneous T-cell lymphoma Phase 3 tria

  8. Slide 8: What is Cutaneous T-Cell Lymphoma (CTCL)?

    CLICK TOCUTANEOUS WHAT IS EDIT MASTER TITLELYMPHOMA T-CELL STYLE (CTCL)? Considered to be incurable, CTCL is a CTCL accounts for general term for T-cell lymphoma that approximately 4% of all non- involve the skin, but may also involve the Hodgkin lymphoma (NHL) blood, lymph nodes, and internal organ

  9. Slide 9: Well-Positioned Among Existing Targeted Therapies

    CLICK TO EDIT MASTER WELL-POSITIONED TITLE AMONG STYLE TARGETED THERAPIES EXISTING With no single SOC, I/ONTAK expected to be an important option as the only IL-2R targeted therapy, especially when existing therapies are poorly tolerated or have limited efficacy CCR4 HDAC targeted1 inhibitor2 I/ONTA

  10. Slide 10: Pivotal Phase 3 Preliminary Trial Results

    CLICK TO EDITPIVOTAL PRELIMINARY MASTERPHASE TITLE STYLE 3 TRIAL RESULTS No new safety signals identified with I/ONTAK compared to ONTAK PHASE 3 PIVOTAL 21 days SINGLE ARM DAY 1 DAY 2 DAY 3 DAY 4 DAY 5 TRIAL N=70 CYCLE DOSING: 9mcg/kg/day IV CYCLE ORR* ORR* in ITT population in “efficacy-evaluable”

  11. Slide 11: Multi-Layered Protection Through IP and Exclusivity

    CLICK TO EDIT MASTER MULTI-LAYERED TITLE STYLE PROTECTION THROUGH IP AND EXCLUSIVITY Proprietary Manufacturing Orphan Drug Designation Process granted for CTCL and PTCL trade secret (eligible for 7 years of marketing exclusivity) BLA Exclusivity Patents Pending limits competition for I/O use as comb

  12. Slide 12: Mino-Lok

    CLICK TO EDIT MASTER TITLE STYLE MINO-LOK® PHASE 3 NASDAQ: CTXR 12

  13. Slide 13: Late-Stage Candidate: Mino-Lok

    CLICK TOPRODUCT LATE-STAGE EDIT MASTER TITLE STYLE CANDIDATE: MINO-LOK ® First and Only antibiotic lock therapy under investigation to sterilize and salvage infected Central Venous Catheters (CVCs) 7 Million ~500,000 CRBSI/CLABSI infections Central Venus Catheters annually in the U.S.** (CVCs) used

  14. Slide 14: Current Standard of Care Is a Poor Option

    CLICK TO EDIT CURRENT MASTER STANDARD OFTITLE CARESTYLE IS A POOR OPTION Removing & replacing infected CVCs has multiple limitations • Limited availability of other vascular sites • Does not address need to maintain infusion therapy • Potential for complications: infectious, thrombotic and mechanica

  15. Slide 15: Potential Gold Standard in CLABSI Treatment

    CLICK TO EDIT POTENTIAL GOLDMASTER TITLE IN STANDARD STYLE CLABSI TREATMENT Mino-Lok® addresses the complications, discomfort and cost of CVC removal and replacement  Limited duration IV therapy 5-7 DAYS  Limits disruption of infusion therapy  Ease of Administration • Locking a catheter is a well

  16. Slide 16: Mino-Lok Phase 2b Trial Results

    CLICK®TO MINO-LOK EDIT 2B PHASE MASTER TITLE STYLE TRIAL RESULTS Mino-Lok® demonstrated a strong safety and efficacy signal Mino-Lok Arm Control Arm Parameter N % N % Patients 30 100% 60 100% 100% Effective in salvaging CVCs in all Cancer Type patients treated with Mino-Lok® - Hematologic 20 67% 48

  17. Slide 17: Mino-Lok Phase 3 Pivotal Trial Underway

    CLICK TO EDIT MINO-LOK MASTER ® PHASE TITLE TRIAL 3 PIVOTAL STYLEUNDERWAY Multi-center, randomized, open label, blinded assessor, active control superiority study Active Arm (n=72) Mino-Lok® Solution Anticipated median Patients with time of CRBSI R 21 days vs. 38 days (n~144) to achieve Control Arm

  18. Slide 18: IP & Regulatory Protections

    CLICK TO EDIT MASTER IP & REGULATORY TITLE STYLE PROTECTIONS Mino-Lok® is supported by a robust intellectual property portfolio with protection through 2036 Description of • Composition of Matter and Creators Patent Patent Numbers Issued Expiry Method of Use patents • US: 7,601,731 2009 2024 that pr

  19. Slide 19: Mino-Lok Summary

    CLICK TO EDIT MINO-LOK MASTER TITLE STYLE ® SUMMARY Potential market-leading antibiotic lock therapy to salvage the CVC in patients with CRBSI/CLABSI • Breaks down biofilm • First and only • Phase 2b trial: • Effective at barriers therapy under 100% effective in penetrating biofilm Key Advantages Cl

  20. Slide 20: Stem Cell Platform

    CLICK TO EDIT MASTER TITLE STYLE STEM CELL PLATFORM PRECLINICAL NASDAQ: CTXR 20

  21. Slide 21: A Differentiated Stem Cell Platform

    CLICK TO EDIT BUILDING MASTER TITLE STEM A DIFFERENTIATED STYLECELL PLATFORM Next generation allogeneic engineered stem cell platform for the treatment of ARDS Licensed induced pluripotent stem cell (iPSC)-derived mesenchymal stem cells (i-MSCs) from Brooklyn ImmunoTherapeutics • mRNA cell reprogram

  22. Slide 22: Interim Results of i-MSC Study in Sheep Model of ARDS

    CLICK INTERIM TO EDIT RESULTS OF MASTER TITLE STYLE Improved Oxygenation Less Systemic Shock i-MSC™ STUDY IN SHEEP P/F ratio Norepinephrine Requirement MODEL OF ARDS Animals receiving i-MSCs™ demonstrated stronger therapeutic effects v. control Peer reviewed publication anticipated in 1H 2022 Reduce

  23. Slide 23: Summary

    CLICK TO EDIT MASTER TITLE STYLE SUMMARY NASDAQ: CTXR 23

  24. Slide 24: Management Team with Proven Track Record

    CLICK TO EDIT MASTER MANAGEMENT TITLE TEAM WITH STYLETRACK RECORD PROVEN LEONARD MAZUR MYRON HOLUBIAK JAIME BARTUSHAK DR. MYRON CZUCZMAN GARY TALARICO EXEC. CHAIRMAN, DIRECTOR PRESIDENT & CEO, DIRECTOR EVP, CFO EVP, CHIEF MEDICAL OFFICER EVP, OPERATIONS KELLY CREIGHTON JAY WADEKAR DR. ALAN LADER PAU

  25. Slide 25: Scientific Advisory Board of Leading KOLs

    CLICK TO EDIT SCIENTIFIC MASTERBOARD ADVISORY TITLE STYLE OF LEADING KOLS INFECTIOUS DISEASE / CANCER ADVISORS CELL THERAPY ADVISORS Isaam Raad, MD Michael A. Matthay, MD University of Texas MD Anderson Cancer Center University of California at San Francisco (UCSF) Mark Rupp, MD Lorraine B. Ware, MD

  26. Slide 26: Financial Summary and Current Capitalization

    CLICK SUMMARY* FINANCIAL TO EDIT MASTER TITLE STYLE % OF FULLY CURRENT CAPITALIZATION SHARES Bandwidth to Execute DILUTED • $127.6M Financing activities FY2021 BASIC SHARES OUTSTANDING 145,979,429 76.1% • $12.2M R&D expense FY 2021 WARRANTS 40,208,347 20.9% • Runway into 2023 OPTIONS 5,755,171 3.0%

  27. Slide 27: Biotech Platform Poised for Growth in 2022

    CLICK TO PLATFORM BIOTECH EDIT MASTER TITLEFOR POISED STYLE GROWTH IN 2022 Multiple value-driving catalysts expected in 2022 I/ONTAK BLA submission anticipated I/ONTAK Pivotal Phase 3 2H 2022 trial topline results anticipated 1H 2022 Mino-Lok® Phase 3 trial completion anticipated 2022 Halo-Lido Phas

  28. Slide 28: Contact

    CLICK TO EDIT MASTER TITLE STYLE Citius Pharmaceuticals, Inc. 11 Commerce Drive First Floor Cranford, NJ 07016 www.citiuspharma.com Investor Relations Contact Ilanit Allen [email protected] NASDAQ: CTXR

Citius Pharmaceuticals — Investor Presentation (January 2022) on 6ix